Research ArticleAccepted Article
Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay and Ricardo Blanco on behalf of the Tofacitinib PsA Clinical Practice Collaborative Group
The Journal of Rheumatology April 2021, jrheum.201204; DOI: https://doi.org/10.3899/jrheum.201204
Eva Galíndez-Agirregoikoa
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Diana Prieto-Peña
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
José Luis Martín-Varillas
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Beatriz Joven
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Olga Rusinovich
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Rafael B. Melero-González
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Francisco Ortiz-Sanjuan
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Raquel Almodóvar
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Juan José Alegre
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Ángels Martínez
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Agustí Sellas-Fernández
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Lara Méndez
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Rosario García-Vicuña
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Belén Atienza-Mateo
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Iñigo Gorostiza
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Miguel Ángel González-Gay
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Ricardo Blanco
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain; Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain; Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain; Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain; Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain; Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain; Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain; Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain; Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain; Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain; Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janssen and UCB Pharma. Dra. Prieto-Peña has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi and UCB Pharma.Dr. Martín-Varillas received grants/research supports from AbbVie, Pfizer, Janssen and Celgene. Dr. Melero-González has received research support from Roche, Astrazeneca, Sanofi Aventis, BMS, Abbvie, Lilly, Faes, Italfarmaco, Gebro, Abbvie, Esteve, UCB, Novartis, Janssen Cilag. Dra. Almodóvar has received research support from abbvie, celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. Dra. García-Vicuña reports grants, personal fees and non-financial support from Abbvie, BMS, Lilly, Novartis, MSD and Pfizer; personal fees from Biogen, Celltrion and Mylan; grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a ‘López-Albo’ Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Pfizer, Roche, Sanofi and Jansen. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD. No financial disclosures declared for the other coauthors. Dr. Eva Galíndez-Agirregoikoa and Dr. Diana Prieto-Peña share first authorship. Correspondence to: Joint corresponding authors: Ricardo Blanco or Prof. Miguel A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander. SPAIN.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay, Ricardo Blanco
The Journal of Rheumatology Apr 2021, jrheum.201204; DOI: 10.3899/jrheum.201204
Accepted manuscript
Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay, Ricardo Blanco
The Journal of Rheumatology Apr 2021, jrheum.201204; DOI: 10.3899/jrheum.201204